GetTopicDetailResponse(id=7ea89e997a4, topicName=陸舜, introduction=陸舜, content=null, image=null, comments=3, allHits=1741, url=https://h5.medsci.cn/topic?id=97997, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=14193, tagList=[TagDto(tagId=14193, tagName=陸舜)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=2212025, encodeId=5cb3221202557, content=<a href='/topic/show?id=7ea89e997a4' target=_blank style='color:#2F92EE;'>#陸舜#</a>教授今年收獲了兩篇<a href='/topic/show?id=4041126241e' target=_blank style='color:#2F92EE;'>#NEJM#</a>，非常厲害! 這篇研究也有可能入選2024年度<a href='/topic/show?id=ae41356995a' target=_blank style='color:#2F92EE;'>#十大#</a>研究, objectTitle=NEJM：陸舜教授牽頭的奧希替尼治療非小細(xì)胞肺癌根治性放化療后靶向治療試驗(yàn)結(jié)果發(fā)表，能降低84%PFS風(fēng)險(xiǎn)（LAURA研究）, objectType=article, longId=828799, objectId=1e9b828e9997, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240604/1717548077668_4754896.jpg, objectUrl=/article/show_article.do?id=1e9b828e9997, replyNumber=0, likeNumber=139, createdTime=2024-06-28, rootId=0, userName=俠膽醫(yī)心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=加利福尼亞, moduleDTOList=[ModuleDTO(moduleId=1e9b828e9997, moduleTitle=NEJM：陸舜教授牽頭的奧希替尼治療非小細(xì)胞肺癌根治性放化療后靶向治療試驗(yàn)結(jié)果發(fā)表，能降低84%PFS風(fēng)險(xiǎn)（LAURA研究）, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=1e9b828e9997)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2212027, encodeId=a686221202efe, content=<a href='/topic/show?id=7ea89e997a4' target=_blank style='color:#2F92EE;'>#陸舜#</a>領(lǐng)銜發(fā)現(xiàn)<a href='/topic/show?id=f46311051235' target=_blank style='color:#2F92EE;'>#埃萬妥單抗#</a>聯(lián)合<a href='/topic/show?id=c64a10641526' target=_blank style='color:#2F92EE;'>#拉澤替尼#</a>一線治療晚期<a href='/topic/show?id=2493130e1a1' target=_blank style='color:#2F92EE;'>#NSCLC#</a>，顯著超越<a href='/topic/show?id=b0054454337' target=_blank style='color:#2F92EE;'>#奧希替尼#</a>，這項(xiàng)研究有望進(jìn)入2024年度<a href='/topic/show?id=ae41356995a' target=_blank style='color:#2F92EE;'>#十大#</a>研究
, objectTitle=NEJM：陸舜領(lǐng)銜發(fā)現(xiàn)埃萬妥單抗聯(lián)合拉澤替尼一線治療晚期NSCLC，顯著超越奧希替尼, objectType=article, longId=832097, objectId=8e5483209ec1, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240627/1719511287567_4754896.png, objectUrl=/article/show_article.do?id=8e5483209ec1, replyNumber=0, likeNumber=170, createdTime=2024-06-28, rootId=0, userName=俠膽醫(yī)心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=加利福尼亞, moduleDTOList=[ModuleDTO(moduleId=8e5483209ec1, moduleTitle=NEJM：陸舜領(lǐng)銜發(fā)現(xiàn)埃萬妥單抗聯(lián)合拉澤替尼一線治療晚期NSCLC，顯著超越奧希替尼, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=8e5483209ec1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2182925, encodeId=133b218292568, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小細(xì)胞肺癌#</a> <a href='/topic/show?id=7ea89e997a4' target=_blank style='color:#2F92EE;'>#陸舜#</a> <a href='/topic/show?id=333a6802212' target=_blank style='color:#2F92EE;'>#特瑞普利單抗#</a>, objectTitle=JAMA：陸舜教授團(tuán)隊(duì)發(fā)現(xiàn)特瑞普利單抗聯(lián)合含鉑雙藥化療用于可手術(shù)II-III期非小細(xì)胞肺癌，EFS風(fēng)險(xiǎn)下了60%（Neotorch研究）, objectType=article, longId=810282, objectId=2ec28102826d, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20240118/220bacf53b854d9c86d4b03a3fbef0fd.jpg, objectUrl=/article/show_article.do?id=2ec28102826d, replyNumber=0, likeNumber=129, createdTime=2024-01-21, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=加利福尼亞, moduleDTOList=[ModuleDTO(moduleId=2ec28102826d, moduleTitle=JAMA：陸舜教授團(tuán)隊(duì)發(fā)現(xiàn)特瑞普利單抗聯(lián)合含鉑雙藥化療用于可手術(shù)II-III期非小細(xì)胞肺癌，EFS風(fēng)險(xiǎn)下了60%（Neotorch研究）, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=2ec28102826d)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2182926, encodeId=41462182926e2, content=<a href='/topic/show?id=7ea89e997a4' target=_blank style='color:#2F92EE;'>#陸舜#</a>教授團(tuán)隊(duì)發(fā)現(xiàn)<a href='/topic/show?id=333a6802212' target=_blank style='color:#2F92EE;'>#特瑞普利單抗#</a>聯(lián)合含鉑雙藥化療用于可手術(shù)II-III期<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小細(xì)胞肺癌#</a>，有望進(jìn)入2024年<a href='/topic/show?id=ae41356995a' target=_blank style='color:#2F92EE;'>#十大#</a>研究。這也充份證明了新輔助免疫治療的價(jià)值, objectTitle=JAMA：陸舜教授團(tuán)隊(duì)發(fā)現(xiàn)特瑞普利單抗聯(lián)合含鉑雙藥化療用于可手術(shù)II-III期非小細(xì)胞肺癌，EFS風(fēng)險(xiǎn)下了60%（Neotorch研究）, objectType=article, longId=810282, objectId=2ec28102826d, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20240118/220bacf53b854d9c86d4b03a3fbef0fd.jpg, objectUrl=/article/show_article.do?id=2ec28102826d, replyNumber=0, likeNumber=148, createdTime=2024-01-21, rootId=0, userName=俠膽醫(yī)心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=加利福尼亞, moduleDTOList=[ModuleDTO(moduleId=2ec28102826d, moduleTitle=JAMA：陸舜教授團(tuán)隊(duì)發(fā)現(xiàn)特瑞普利單抗聯(lián)合含鉑雙藥化療用于可手術(shù)II-III期非小細(xì)胞肺癌，EFS風(fēng)險(xiǎn)下了60%（Neotorch研究）, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=2ec28102826d)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
